Greenstreet Yvonne, Chief Executive Officer, has demonstrated a clear selling bias in her recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 96 transactions, Yvonne has exclusively traded shares of Alnylam Pharmaceuticals (ALNY), with total buy and sell values amounting to $3,505,449.23 and $28,073,064.80, respectively. Notably, her recent activity has been dominated by sales, with 20 sell transactions recorded since January 12, 2026, and no buys during this period. These sales have ranged in value from $35,515.08 to $2,157,542.21, with several transactions exceeding $100,000, such as the $545,445.89 sale on March 2, 2026, and the $315,096.32 sale on March 4, 2026.
The timing and volume of these transactions suggest a strategic reduction in Yvonne’s holdings in ALNY. While the filings include a few acquisitions (coded as "A") and a merger-related transaction (coded as "M"), these entries carry no monetary value, further underscoring the focus on divestment. The absence of recent purchases contrasts sharply with her earlier buying activity, which totaled over $3.5 million. This shift in trading behavior aligns with a broader trend of reducing exposure to ALNY, though the filings provide no insight into the rationale behind these moves. Yvonne’s consistent and high-value sales highlight her significant stake in the company and her active management of that position.
AI-assisted summary